Thermo Fisher Scientific announced an agreement with global healthcare provider Abbott Laboratories to make its Procalcitonin (PCT) assay available with Abbott’s immunochemistry analyzers.
The company’s Thermo Scientific B.R.A.H.M.S Procalcitonin (PCT) assay will be available on Abbott’s ARCHITECT “i” and “ci” series of immunochemistry analyzers.
Abbott’s high-, medium-, and low-volume integrated diagnostic testing solutions leverage software, reagents, and sample carrier to enable labs to standardize lab operations on a single platform.
In turn, laboratories are able to optimize processes, minimize errors and reduce result variability, an increasingly important consideration as clinicians rely more heavily on laboratory diagnostics to guide their treatment decisions.
Thermo Fisher will manufacture the Abbott ARCHITECT B.R.A.H.M.S PCT assay and has exclusive distribution rights in relevant European markets.
Severe sepsis strikes more than 750,000 Americans each year, and between 28 to 50 percent of patients die within the first month of diagnosis. Hospital costs to treat severe sepsis in the U.S. are estimated at $16 billion dollars annually.
Much of this cost is attributed to misdiagnosis or delayed diagnosis, making faster, more accurate detection a national, if not global, imperative.
Research published in Critical Care Medicine showed that each hour of delay in therapy can decrease chances of patient survival by 7.6 percent.